A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH PERSISTENT MODERATE TO SEVERE ATOPIC DERMATITIS THAT IS INADEQUATELY CONTROLLED BY TOPICAL CORTICOSTEROIDS PROTOCOL NUMBER:

Clamon, Gerald H

3215 - Internal Medicine

Merck Sharp & Dohme Company

Immune checkpoints in premalignant head and neck lesions

Comellas, Alejandro

3215 - Internal Medicine

National Jewish Health

COPDGene

Coryell, William H

3260 - Psychiatry

Janssen Research and Development, LLC

A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment